Lexeo Therapeutics, Inc. Common Stock
- LXEO
- NASDAQ
- Biotechnology
- Gene Therapy (Cardiovascular)
- AAV-based Treatments
$2.76
Today +4.55%Quote Oct 19, 2026, 08:00 PM UTC
−34.29%over the last month
Max drawdown −37.4%From 1-month high −34.3%3 months −40.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
63
Market value
$226.6M
Quote Oct 19
Floor
$2.56
7.2% below price
Resistance
$2.81
1.7% above price
Price vs analyst targets
5 analysts
Lowest target
$10.00Highest target
$30.00
$10.00Highest target
$30.00
- Price $2.76
- Average target $21.13
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 666% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LXEOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free